Ketoprofen |
NSAID |
COX-1 >> COX-2 |
|
198 |
Aspirin |
NSAID |
COX-1 >> COX-2 |
|
186 |
Naproxen |
NSAID |
COX-1, COX-2 |
|
198 |
Ibuprofen |
NSAID |
COX-1, COX-2 |
|
198 |
Diclofenac |
NSAID |
COX-1, COX-2 |
|
185 |
Ketorolac |
NSAID |
COX-1, COX-2 |
|
199 |
Indomethacin |
NSAID |
COX-1, COX-2 |
|
200 |
Dipyrone (metamizole) |
NSAID |
COX-1, COX-2 |
|
201 |
Piroxicam |
NSAID |
COX-2 > COX-1 |
|
186 |
Meloxicam |
NSAID |
COX-2 >> COX-1 |
|
186 |
Nimesulide |
NSAID |
COX-2 >> COX-1 |
|
183 |
Celecoxib |
NSAID |
COX-2 >>
>COX-1 |
|
183 |
Etoricoxib |
NSAID |
COX-2 >>
>COX-1 |
|
183 |
Paracetamol (acetaminophen) |
Related to NSAIDs |
COX-1,
COX-2-non-substrate mechanism |
|
38,39 |
Montelukast |
LTRA |
CysLTR1 |
Additional immunomodulatory properties
have been suggested |
46 |
Zafirlukast |
LTRA |
CysLT1 |
|
46 |
Pranlukast |
LTRA |
CysLT1 |
|
46 |
Zileuton |
Leukotriene synthesis inhibitor |
5-LOX |
|
202 |
Fevipiprant |
Prostaglandin receptor antagonist |
DP2 |
Phase 3 clinical
trials |
203 |
Asapiprant |
Prostaglandin receptor antagonist |
DP1 |
Phase 2 clinical
trials |
ClinicalTrials.gov Identifier: NCT04705597 |
Laropiprant |
Prostaglandin receptor antagonist |
DP1 |
Temporarily
approved in Europe as a component of a hypolipidemic drug |
204 |
Vidupiprant |
Prostaglandin receptor antagonist |
DP2 > DP1 |
Phase 2 clinical trials |
ClinicalTrials.gov Identifier:
NCT01018550 |